Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Huntsman Cancer Institute (University of Utah)

Sites in Salt Lake City, UT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:22 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1138
Shown on this page
12
Current sort
Recently updated
Campus scope
Huntsman Cancer Institute (University of Utah), Salt Lake City, UT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Huntsman Cancer Institute (University of Utah), Salt Lake City, UT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 589–600 of 1,138 matching trials with a site at Huntsman Cancer Institute (University of Utah), Salt Lake City, UT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional Results available

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

NCT03203473
Site status not listed — check the official record
View directory record Official record
Conditions
Renal Cancer
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Toni Choueiri, MD
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
8
States / cities
La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 2, 2026, 9:22 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

NCT05524883
Site status not listed — check the official record
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
DYNE-251, Placebo
Drug
Lead sponsor
Dyne Therapeutics
Industry
Eligibility
4 Years to 16 Years · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 2, 2026, 9:22 PM EST
Recruiting Phase 2 Interventional

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177
Status at this site: Recruiting
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 2, 2026, 9:22 PM EST
Active, not recruiting Phase 2 Interventional

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

NCT03967223
Site status not listed — check the official record
View directory record Official record
Conditions
Neoplasms
Interventions
Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
Drug
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 2, 2026, 9:22 PM EST
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

NCT06328608
Status at this site: Recruiting
View directory record Official record
Conditions
Fabry Disease
Interventions
PRX-102 1 mg/kg every two weeks
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
6
States / cities
Phoenix, Arizona • Atlanta, Georgia • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 2, 2026, 9:22 PM EST
Active, not recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

NCT05711940
Site status not listed — check the official record
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
62
States / cities
Gilbert, Arizona • Bellflower, California • Encino, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 2, 2026, 9:22 PM EST
Recruiting Not applicable Interventional

Feasibility of an Interdisciplinary Intervention to Improve Care Transitions for Hospitalized Patients With Substance Use Disorders

NCT07575373
Status at this site: Recruiting
View directory record Official record
Conditions
Substance Use Disorders
Interventions
IntACT, Usual Care
Behavioral
Lead sponsor
Michael Incze
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 2, 2026, 9:22 PM EST
Recruiting Phase 1 Interventional

Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)

NCT06607549
Status at this site: Recruiting
View directory record Official record
Conditions
Central Nervous System Lymphoma
Interventions
Loncastuximab tesirine and rituximab (Lonca-R)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Providence, Rhode Island • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 2, 2026, 9:22 PM EST
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT01892722
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 2, 2026, 9:22 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Rural Adult and Youth Sun Protection Study

NCT06439979
Status at this site: Recruiting
View directory record Official record
Conditions
Melanoma (Skin), Skin Cancer
Interventions
RAYS Intervention
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
3 Years to 7 Years
Enrollment
843 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
2
States / cities
Salt Lake City, Utah • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 2, 2026, 9:22 PM EST
Recruiting Not applicable Interventional

Developing an Innovative Decision Support Tool for Pediatric Neuromuscular Scoliosis

NCT07167927
Status at this site: Recruiting
View directory record Official record
Conditions
Children With Medical Complexity (CMC), Multiple Chronic Conditions, Neuromuscular Scoliosis, Shared Decision Making, Decision Support Systems, Clinical, Decision Aids
Interventions
Decision support tool
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
8 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 2, 2026, 9:22 PM EST
Not yet recruiting Phase 4 Interventional

Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

NCT07756359
Site status not listed — check the official record
View directory record Official record
Conditions
Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, Inflammatory
Interventions
Tirzepatide, Loperamide, Diphenoxylate/Atropine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Beverly Hills, California • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 2, 2026, 9:22 PM EST

About this Huntsman Cancer Institute (University of Utah) institution page

What this page lists
ClinicalTrials.gov records that list Huntsman Cancer Institute (University of Utah) in Salt Lake City, UT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.